Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 25;55(6):2000189.
doi: 10.1183/13993003.00189-2020. Print 2020 Jun.

Diagnosis of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism

Affiliations
Free article
Review

Diagnosis of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism

Fredrikus A Klok et al. Eur Respir J. .
Free article

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is the most severe long-term complication of acute pulmonary embolism (PE). Untreated CTEPH is fatal, but, if diagnosed in time, successful surgical (pulmonary endarterectomy), medical (pulmonary hypertension drugs) and/or interventional (balloon pulmonary angioplasty) therapies have been shown to improve clinical outcomes, especially in case of successful pulmonary endarterectomy. Early diagnosis has however been demonstrated to be challenging. Poor awareness of the disease by patients and physicians, high prevalence of the post-PE syndrome (i.e. persistent dyspnoea, functional limitations and/or decreased quality of life following an acute PE diagnosis), lack of clear guideline recommendations as well as inefficient application of diagnostic tests in clinical practice lead to a reported staggering diagnostic delay >1 year. Hence, there is a great need to improve current clinical practice and diagnose CTEPH earlier. In this review, we will focus on the clinical presentation of and risk factors for CTEPH, and provide best practices for PE follow-up programmes from expert centres, based on a clinical case.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: F.A. Klok reports research grants from Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi-Sankyo, MSD and Actelion, the Dutch Heart foundation and the Dutch Thrombosis association. Conflict of interest: F. Couturaud reports grants from Pfizer, personal fees from Bayer and Leopharma, personal fees from and has contributed to clinical trials for BMS and AstraZeneca, and has contributed to clinical trials for Boehringer, Daiichi, GSK and Actelion, outside the submitted work. Conflict of interest: M. Delcroix reports grants and personal fees for research, lectures and consultancy from Actelion/J&J, personal fees for research, lectures and consultancy from Bayer, personal fees for lectures and consultancy from MSD, personal fees for research from Reata, personal fees for research and consultancy from Bellarophon, personal fees for consultancy from Acceleron, outside the submitted work. Conflict of interest: M. Humbert reports grants and personal fees from Bayer and GSK, personal fees from Acceleron, Actelion, MSD and United Therapeutics, outside the submitted work.

Publication types

LinkOut - more resources